Today, URCH Publishing Ltd announces the availability of a major new strategic report on creating a virtual pharmaceutical company
(1888PressRelease) September 13, 2008 - Today, URCH Publishing Ltd announces the availability of a major new strategic report on creating a virtual pharmaceutical company. “Virtual Pharma: the radical route to success” (http://www.urchpublishing.com/publications/management/virtual_pharma_report) proposes that there is a solution to declining profitability by creating a virtual company: the company that retains key skills but outsources everything else, including: discovery research, drug development, manufacturing and sales and marketing.
The 91 page report is essential reading for anyone in the biotech, pharmaceutical and clinical outsourcing industries from corporate management through development and research to marketing and sales. It gives an authoritative, detailed and clear explanation of the issues surrounding the virtual pharma business and has a number of key case studies.
1.0 Introduction
1.1 Review of the challenges facing the pharma industry
1.1.1 Globalisation and emerging markets
1.1.2 Declining R&D productivity and innovation
1.1.3 Personalised medicine and the growth of the speciality sector
1.1.4 The need to reduce sales and marketing expense
1.1.5 Increasing generic competition
1.1.6 Cost containment and the increased use of cost benefit analysis
1.1.7 Changes in the manufacture of drugs
1.2 The Virtual Pharma business model
1.3 Potential pitfalls of a virtual pharma model
1.4 Implementation of a virtual pharma model
2.0 Virtual Discovery Research
2.1 The drug discovery process
2.2 Key advantages of a virtual drug discovery model
2.2.1 Access to a wide range of drug discovery expertise and technologies
2.2.2 Reduced capital expenditure
2.2.3 Greater operational and financial flexibility
2.2.4 A more efficient R&D process
2.2.5 Reduced organisational complexity and bureaucracy
2.3 Key disadvantages and risks of a virtual drug discovery model
2.3.1 Potential for loss of control
2.3.2 Over-dependence on the service provider
2.3.3 Potential for decline in quality
2.3.4 Higher transactional costs
2.3.5 Reduced opportunity to develop internal expertise
2.3.6 Potential for breaches of confidentiality
2.4 Implementation challenges of a virtual drug discovery model
2.4.1 Choosing the right service provider
2.4.2 Getting the right agreement in place
2.4.3 Managing relationships
2.4.4 Keeping control
2.4.5 Monitoring quality
3.0 Virtual Drug Development
3.1 Advantages of a virtual drug development model
3.1.1 Accelerate the development process
3.1.2 Benefit from greater depth and breadth of development expertise
3.1.3 Conduct clinical research in lower cost countries
3.2 Key disadvantages and risks of a virtual drug development model
3.3 Implementation challenges of a virtual drug development model
3.3.1 Choosing the right service provider
3.3.2 Getting the right agreement in place
3.3.3 Determine clear study specifications and endpoints � and future plans
3.3.4 Managing relationships
3.3.5 Assessing the cost-benefit trade-off
3.3.6 Working with CROs in emerging markets
4.0 Virtual Manufacturing
4.1 Advantages of a virtual drug manufacturing model
4.1.1 Gain access to capacity with low upfront investment
4.1.2 Reduce the operational and financial risk of manufacturing
4.1.3 Gain access to cutting-edge manufacturing expertise and technology
4.1.4 Benefit from financial and operational flexibility
4.1.5 Benefit from low-cost manufacturing in emerging countries
4.2 Disadvantages and risks of a virtual drug manufacturing model
4.2.1 Loss of control
4.2.2 Potential for breaches of confidentiality
4.2.3 Risks of outsourcing manufacturing to emerging markets
4.2.4 Potential shortfalls in biologics manufacturing capacity
4.3 Implementation challenges of a virtual drug manufacturing model
4.3.1 Choosing the right service provider
4.3.2 Getting the right agreement in place
4.3.3 Invest resources in managing relationships
4.3.4 Internal manufacturing expertise is desirable
5.0 Virtual Sales and Marketing
5.1 Advantages of a virtual sales model
5.1.1 Cost and efficiency savings
5.1.2 Increase flexibility to adapt to changing market conditions
5.1.3 Retain control and maximise returns
5.2 Disadvantages of a virtual sales model
5.2.1 Potential for loss of control of product message and branding
5.2.2 Risk of breaches of confidentiality of proprietary information
5.3 Implementation challenges of a virtual sales model
5.3.1 Choosing the right service provider
5.3.2 Getting the right agreement in place
5.3.3 Handing over to the CSO
5.3.4 Managing relationships
More information about Virtual Pharma: the radical route to success priced at £795 can be found at:
http://www.urchpublishing.com/publications/management/virtual_pharma_report
About URCH Publishing Ltd
URCH Publishing Ltd is an independent business information publisher dedicated to delivering quality information products to the global pharmaceuticals industry. The company is based in London, UK. For more information contact URCH Publishing on +44 (0) 20 7060 1099 or email press ( @ ) urchpublishing dot com.
Today, URCH Publishing Ltd announces the availability of a major new strategic report on creating a virtual pharmaceutical company 
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam